Synthesis of A-9758, an Inverse Agonist of Retinoic Acid-Related Orphan Receptor γt.

ACS Omega

Drug Discovery Science and Technology, AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States.

Published: December 2022

A-9758 is an inverse agonist of retinoic acid-related orphan receptor γt with well-characterized in vitro and in vivo anti-inflammatory activity. A chromatography-free decagram-scale synthesis of this compound was developed to support pre-clinical research activities. This route was designed to enable late-stage structure-activity relationship studies of the amide moiety and convergently uses a reductive alkylation sequence between indole and benzaldehyde intermediates. A key advantage of this strategy is the fact that the indole precursor can be alkylated at C2, as required for A-9758, or at C3 to provide access to an isomeric chemical series. Access to the critical indole fragment was expedited via an underutilized SnAr/reductive cyclization cascade sequence, and the benzaldehyde fragment was prepared in two steps from inexpensive 2,4-dichlorobenzoic acid.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730458PMC
http://dx.doi.org/10.1021/acsomega.2c06060DOI Listing

Publication Analysis

Top Keywords

a-9758 inverse
8
inverse agonist
8
agonist retinoic
8
retinoic acid-related
8
acid-related orphan
8
orphan receptor
8
receptor γt
8
synthesis a-9758
4
γt a-9758
4
γt well-characterized
4

Similar Publications

Synthesis of A-9758, an Inverse Agonist of Retinoic Acid-Related Orphan Receptor γt.

ACS Omega

December 2022

Drug Discovery Science and Technology, AbbVie, Inc., 1 North Waukegan Road, North Chicago, Illinois 60064, United States.

A-9758 is an inverse agonist of retinoic acid-related orphan receptor γt with well-characterized in vitro and in vivo anti-inflammatory activity. A chromatography-free decagram-scale synthesis of this compound was developed to support pre-clinical research activities. This route was designed to enable late-stage structure-activity relationship studies of the amide moiety and convergently uses a reductive alkylation sequence between indole and benzaldehyde intermediates.

View Article and Find Full Text PDF

Inhibition of Interleukin-23-Mediated Inflammation with a Novel Small Molecule Inverse Agonist of RORt.

J Pharmacol Exp Ther

October 2019

AbbVie Inc., North Chicago, Illinois (S.B.G., Y.W., L.L., S.H., Z.S., J.W., K.S., S.P.M., P.H., K.D., M.E.K., D.G., R.E.); Inventiva, Daix, France (J.-M.L., D.B., D.P., P.J.M., S.J.); and AbbVie Bioresearch Center, Worcester, Massachusetts (C.W., R.M., C.G., M.A.A., E.B., K.C.).

Blockade of interleukin (IL)-23 or IL-17 with biologics is clinically validated as a treatment of psoriasis. However, the clinical impact of targeting other nodes within the IL-23/IL-17 pathway, especially with small molecules, is less defined. We report on a novel small molecule inverse agonist of retinoid acid-related orphan receptor (ROR) t and its efficacy in preclinical models of psoriasis and arthritis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!